KMTS Kestra Medical Technologies, Ltd. - Common Stock

Why Kestra Medical Technologies Stock Is Back In Focus Kestra Medical Technologies (KMTS) has drawn fresh attention after first quarter results showed sales of US$30.97 million and a net loss of US$44.09 million, alongside a higher fiscal 2027 revenue outlook. The recent update has landed after a strong run in Kestra Medical Technologies’ share price, with a 90 day share price return of 19.72%. This comes even though the 30 day share price return is down 8.23% and the 1 year total shareholder...

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported on September 14 that fiscal first-quarter 2027 revenue increased 60% to $31.0 million. Gross margin reached 56.5%, up from 45.7%, for the quarter ended July 31, 2026. Management raised fiscal 2027 revenue guidance to $141 million from $137 million, implying 48% annual growth. The outlook strengthens the commercial story, […]

Moby summary of KESTRA MEDICAL TECHNOLOGIES, LTD.'s Q1 2027 earnings call

Kestra Medical Technologies Ltd (KMTS) posted 60% revenue growth, a record 11th straight quarter of gross margin expansion, and raised its FY27 outlook on surging in-network mix and faster rep ramps.

Kestra Medical Technologies (NASDAQ:KMTS) reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequentially from the fourth quarter. The company raised its full-year revenue outloo

Kestra Medical Technologies, Ltd. (KMTS) delivered earnings and revenue surprises of -22.95% and +6.66%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?

Forgent stock had a successful IPO, but the AI infrastructure stock is down sharply ahead of its upcoming earnings report.

Kestra Medical Technologies, Ltd. (KMTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Phibro (PAHC) delivered earnings and revenue surprises of +18.06% and +8.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Apple downgraded, HPE upgraded: Wall Street's top analyst calls

Moby summary of KESTRA MEDICAL TECHNOLOGIES, LTD.'s Q4 2026 earnings call

Despite a significant net loss, Kestra Medical Technologies Ltd (KMTS) reports robust revenue growth and strategic advancements in sales territories and product innovation.

Kestra Medical Technologies (NASDAQ:KMTS) reported a sharp increase in fourth-quarter revenue and issued fiscal 2027 guidance calling for continued growth, as executives said demand for the company’s ASSURE wearable cardioverter defibrillator system is being driven by new accounts, deeper penetratio

Kestra Medical Technologies, Ltd. (KMTS) delivered earnings and revenue surprises of -13.56% and +8.05%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?